New discoveries reveal how acute myeloid leukemia walks a fine line between growth and cell death

Researchers revealed new insights into how acute myeloid leukemia (AML) develops and progresses, according to a study published in Molecular Cell on July 20, 2021. They describe a mechanism by which AML cells regulate a cancer-related protein, mutant IDH2, to increase the buildup of blood cancer cells—a distinguishing characteristic of the disease.

UM Greenebaum Comprehensive Cancer Center Earns Renewal of Highest Designation for Cancer Center Excellence from National Cancer Institute

The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) has earned renewal of its National Cancer Institute (NCI) designation as a Comprehensive Cancer Center for another five years. The prestigious distinction recognizes the cancer center’s high caliber of scientific leadership and robust programs in basic, clinical and population science research, placing it in the top echelon of cancer centers nationwide.

American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27

Registration opens today for the American Society for Radiation Oncology’s (ASTRO) 63rd Annual Meeting, which will return to an in-person conference at McCormick Place West in Chicago, October 24-27, 2021. Media resources and registration are available at www.astro.org/astro2021press, and general registration is available at www.astro.org/annualmeeting.

Prominent Scientist Julio Aguirre-Ghiso, Ph.D., To Lead New Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center

Albert Einstein Cancer Center (AECC), Albert Einstein College of Medicine, and Montefiore Health System today announced that leading cancer biologist Julio Aguirre-Ghiso, Ph.D., has been named founding director of the Cancer Dormancy and Tumor Microenvironment Institute (CDTMI), director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program. He will also be an endowed professor of cell biology at Einstein. He will assume his new roles on October 1, 2021.

Capturing the Chemistry of Light-Activated Cancer Drugs with Ruomei Gao

Ruomei Gao—an associate professor at SUNY College at Old Westbury—has been using facilities at the Center for Functional Nanomaterials at Brookhaven Lab to investigate two primary processes of photosensitization for cancer therapy and prevention.

Global Event Will Advance Early Age Onset Colorectal Cancer Research

In many countries around the world, patients under age 50 are fighting, some dying, of colon and rectal cancers. Early-Age Onset Colorectal Cancer is an urgent issue in cancer research and patient care around the globe. We all want to know why this is happening, fully aware that for some, time is running out.

Tip Sheet: Massive unmet needs in COVID-19 treatment, osteoporosis drugs for breast cancer, new bladder cancer target — and AIDS at 40

SEATTLE — June 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news. If you are covering news at the annual meeting of the American Society of Clinical Oncology (June 4-8), check out our ASCO page highlighting Fred Hutch presentations and feel free to reach out to our media team for help sourcing experts: [email protected]

LUDWIG CANCER RESEARCH STUDY DISCOVERS HOW TO REVIVE POTENT BUT INERT ANTI-CANCER IMMUNE CELLS FOR THERAPY

A Ludwig Cancer Research study has discovered how to revive a powerful but functionally inert subset of anti-cancer immune cells that are often found within tumors for cancer therapy.

Led by Ludwig Lausanne’s Ping-Chih Ho and Li Tang of the École Polytechnique Fédérale de Lausanne, the study describes how an immune factor known as interleukin-10 orchestrates the functional revival of “terminally exhausted” tumor-infiltrating T lymphocytes (TILs), which have so far proved impervious to stimulation by immunotherapies. It also demonstrates that the factor, when applied in combination with cell therapies, can eliminate tumors in mouse models of melanoma and colon cancer. The findings are reported in the current issue of Nature Immunology.

Cleveland Clinic experts available to comment on cancer research presented at ASCO Annual Meeting

Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021. Key research from Cleveland Clinic focuses on advancements in the prevention and…

SHRO’s Giordano Meets with Speaker Pelosi at Italian Embassy in Washington

At the prestigious setting of Villa Firenze, the Italian Embassy in Washington, DC, on the occasion of a farewell party for outgoing Ambassador Armando Varricchio, Professor Antonio Giordano, Neapolitan oncologist, director of the Sbarro Institute for Cancer Research, Temple University, professor of Pathological Anatomy at the University of Siena, Italy, and member of the board of directors of the National Italian American Foundation (NIAF) was in attendance among the many high-ranking government officials and honored guests.

Rutgers Cancer Institute of New Jersey Experts Available for Comment on Research Topics during National Cancer Research Month

New Brunswick, N.J., April 29, 2021 – Many years of research devoted to cancer has led to valuable insight and life-saving measures. To highlight the importance of lifesaving research to the millions of people around the world impacted by cancer,…

Patient reactions to colorectal cancer estimated to become the leading cause of cancer-related deaths for those 20-49 by 2030

In a recent JAMA publication, researchers predict, “For the age group 20-49, colorectal cancer was estimated to become the leading cause of cancer-related deaths by 2030.” Fight Colorectal Cancer (Fight CRC), the nation’s leading advocacy organization, is committed to amplifying…

Rutgers Cancer Institute of New Jersey Awarded $1.3M for Cancer Metabolism and Growth Research Program

Rutgers Cancer Institute has received a $1.3 million, five-year grant from the National Cancer Institute to support the Cancer Metabolism and Growth and Tumor Host Interactions Training Program which will provide postdoctoral candidates the highest quality training and research experience.

Tip Sheet: New COVID-19 transmission study, returning to school, video of biorepositories — and a new weight loss study

SEATTLE —  April 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news. April is National Minority Health Month, with a focus on the disproportionate impacts of COVID-19 on communities of color. See more details below on related Fred Hutch programming.Save the date for our monthly public science event, “Science Says” on Tuesday, April 27.

Rutgers Cancer Institute of New Jersey Research Leader Elected as a Fellow to the American Association for Cancer Research Academy

Deputy director, chief scientific officer, and associate director for Basic Research at Rutgers Cancer Institute of New Jersey has been elected to the 2021 class of Fellows of the American Association for Cancer Research (AACR) Academy, a prestigious accolade offered only to individuals whose work has had a significant and enduring impact on cancer research.

Proton therapy induces biologic response to attack treatment-resistant cancers

Mayo Clinic researchers have developed a novel proton therapy technique to more specifically target cancer cells that resist other forms of treatment. The technique is called LEAP, an acronym for “biologically enhanced particle therapy.” The findings are published today in Cancer Research, the journal of the American Association for Cancer Research.

Roswell Park Awarded Nearly $2 Million to Study Cause of Racial Disparities in Breast Cancer

A research team headed by Roswell Park Comprehensive Cancer Center epidemiologist Zhihong Gong, PhD, has been awarded a five-year, $1.9 million grant from the National Cancer Institute for an investigation into the role that certain genetic molecules play in breast cancer disparities.

Cancer Research Expands Body’s Own Immune System to Kill Tumors

Scientists are hoping advances in cancer research could lead to a day when a patient’s own immune system could be used to fight and destroy a wide range of tumors. Cancer immunotherapy has some remarkable successes, but its effectiveness has been limited to a relatively small handful of cancers. In APL Bioengineering, researchers describe how advances in engineering models of tumors can greatly expand cancer immunotherapy’s effectiveness to a wider range of cancers.

Robin Roberts, Charles Barkley and TNT’s Ernie Johnson Jr. team up to #EndCancer on Feb. 4

An all-star lineup of basketball greats, several of whom are courageous cancer survivors, will share their stories Feb. 4 at The University of Texas MD Anderson Cancer Center’s A Conversation with a Living Legend event. Robin Roberts, an anchor of “Good Morning America,” will join Emmy Award-winning sportscaster Ernie Johnson Jr. for a virtual fireside chat with a special guest appearance by 11-time NBA All-Star Charles Barkley.

Roy S. Herbst, MD, PhD, Receives 2020 ACCC Clinical Research Award

Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.

Henry Ford Health System Receives $16 Million Gift to Benefit Henry Ford Pancreatic Cancer Center

Henry Ford Health System today announced a $16 million gift to its Henry Ford Pancreatic Cancer Center (HFPCC), which was launched in 2018 by an initial $20 million gift from the same donor, who wishes to remain anonymous. The gift will bolster the HFPCC’s clinical and translational research endeavors in the fight against this devastating disease, for which the five-year survival rate is only 9 percent.

A Conversation With a Living Legend honoring Admiral William H. McRaven raises $1 million

The North Texas A Conversation With a Living Legend® raised $1 million this week in a virtual version of the signature fundraising event benefiting The University of Texas
MD Anderson Cancer Center. The 31st annual event honored Admiral William H. McRaven, U.S. Navy, Retired, in an interview Nov. 16 with CBS News’ Bob Schieffer. Proceeds will benefit MD Anderson’s Moon Shots Program®, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients’ lives.

Roswell Park Sees Suggestion of Benefit in First Clinical Trial to Combine Beta-Blocker and Checkpoint Inhibitor

The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive. A team of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to disrupt that dynamic so that cancer treatments can be more effective. Their latest work, published today in Clinical Cancer Research, a journal of the American Association for Cancer Research, suggests that a drug widely prescribed to control blood pressure may improve patients’ response to cancer immunotherapy.

Adding image guidance to post-operative radiation therapy can reduce side effects for women with cervical cancer

A phase III trial from India shows that an advanced radiation therapy technique leads to fewer gastrointestinal side effects in women who receive radiation after undergoing hysterectomy for cervical cancer. Findings from the PARCER trial (NCT01279135) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Group trial bolsters case for stereotactic radiation therapy for tumors that travel to the lungs

A new study, conducted across 13 medical centers in Australia and New Zealand, strengthens the case for radiation therapy as a treatment for cancer that has begun to spread throughout the body. Findings of the SAFRON II trial (NCT01965223) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Radiosurgery reduces cognitive decline without compromising survival for patients with 4+ brain metastases

Results of a new randomized phase III trial suggest that stereotactic radiosurgery (SRS) should replace whole brain radiation therapy (WBRT) as the standard of care for patients with four or more brain metastases. Results from the clinical trial (NCT01592968) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Adding advanced PET scans to radiation treatment plans for prostate cancer increases failure-free survival rates

Adding the advanced PET radiotracer fluciclovine to conventional imaging to help guide radiation treatments for recurrent prostate cancer can improve disease-free survival rates, a new study finds. Findings from the randomized phase II/III EMPIRE-1 trial (NCT01666808) will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

Radiation oncology research and clinical trial results to be featured at ASTRO’s Annual Meeting

The American Society for Radiation Oncology (ASTRO) announced today the press program for its 2020 Annual Meeting, which will feature studies on cancer treatment advances and discussions of topical issues including COVID-19. Researchers will present their findings via live webcasts on October 26 and 27. Register for press access at www.astro.org/annnualmeetingpress.

Rutgers Cancer Institute of New Jersey Awarded $1.6M for Rutgers Youth Enjoy Science (RUYES) Program for Underrepresented Youth and Educators

The Rutgers Youth Enjoy Science (RUYES) program, funded by the National Cancer Institute, will engage underrepresented minority undergraduate and high school students in cutting-edge cancer research, curriculum support, and professional development activities.

MD Anderson and Taiho Pharmaceutical announce collaboration to accelerate development of novel therapies for brain metastasis and other unmet medical needs

The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration to accelerate the development of treatments for significant unmet medical needs in oncology, including patients with brain metastases and those with cancers refractory to available therapies.